OXO-001
Enhancement of embryo implantation in women undergoing IVF/ICSI
Key Facts
About OXOLIFE
OXOLIFE is a pioneering Spanish biotech addressing a critical unmet need in reproductive medicine: the lack of treatments to improve embryo implantation, which accounts for approximately 50% of pregnancy losses in IVF cycles. Its lead candidate, OXO-001, is an oral, non-hormonal pill that acts directly on the uterine lining and has demonstrated efficacy in increasing implantation and pregnancy rates in a Phase II trial. The company is also exploring OXO-001's potential to treat infertility in PCOS patients, positioning itself in the high-growth femtech and fertility markets with a first-in-class therapeutic approach.
View full company profileAbout OXOLIFE
OXOLIFE is a pioneering Spanish biotech addressing a critical unmet need in reproductive medicine: the lack of treatments to improve embryo implantation, which accounts for approximately 50% of pregnancy losses in IVF cycles. Its lead candidate, OXO-001, is an oral, non-hormonal pill that acts directly on the uterine lining and has demonstrated efficacy in increasing implantation and pregnancy rates in a Phase II trial. The company is also exploring OXO-001's potential to treat infertility in PCOS patients, positioning itself in the high-growth femtech and fertility markets with a first-in-class therapeutic approach.
View full company profile